Likewise, the Hsp90 inhibitors being used for asthma, IPF or PAH may also block heme-maturation of sGC, creating pathologic heme-free sGC, and consequently reduce sGC activation in these diseased conditions. This evidence concerns the gene HSP90AA1 and pulmonary arterial hypertension.